Subtype
Head and Neck Mucosal Squamous Cell Carcinoma
CI-CAN-00002825Explore in graph →
160 active trials3 evidence items
- NCIt
- C214954
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00002825Explore in graph →
Clinical trials
457 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (60)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03370276 | Cetuximab & Nivolumab in Patients With Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma | completed | Phase 1 / Phase 2 | 95 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Apr 2, 2026 | clinicaltrials |
| NCT03978689 | A Phase 1 Study in Patients With HPV16+ Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma | completed | Phase 1 | 80 | Cue BiopharmaINDUSTRY | 1 | Jan 22, 2026 | clinicaltrials |
| NCT03381183 | IRX-2 Regimen and Durvalumab, for Incurable H&N Squamous Cell Carcinoma | completed | Phase 1 | 19 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Dec 5, 2025 | clinicaltrials |
| NCT02381535 | Onalespib in Treating Patients With Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck Receiving Radiation Therapy and Cisplatin | completed | Phase 1 | 2 | National Cancer Institute (NCI)NIH | 2 | Feb 11, 2025 | clinicaltrials |
| NCT02538510 | Pembrolizumab and Vorinostat in Treating Patients With Recurrent Squamous Cell Head and Neck Cancer or Salivary Gland Cancer That Is Metastatic and/or Cannot Be Removed by Surgery | completed | Phase 1 / Phase 2 | 50 | University of WashingtonOTHER | 1 | Nov 26, 2024 | clinicaltrials |
| NCT02113878 | Phase Ib Study of BKM120 With Cisplatin and XRT in High Risk Locally Advanced Squamous Cell Cancer of Head and Neck | completed | Phase 1 | 23 | Dana-Farber Cancer InstituteOTHER | 1 | Nov 5, 2024 | clinicaltrials |
| NCT04870840 | Image-guided Proton Therapy for the Treatment of Locally Advanced Unresectable Head and Neck Cancer | completed | Phase 1 | 3 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 29, 2024 | clinicaltrials |
| NCT03028766 | WEE1 Inhibitor with Cisplatin and Radiotherapy: a Trial in Head and Neck Cancer(WISTERIA) | completed | Phase 1 | 9 | University of BirminghamOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT01847326 | Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Carboplatin Followed By Chemoradiation in Treating Patients With Recurrent Head and Neck Cancer | completed | Phase 1 | 48 | University of ChicagoOTHER | 1 | Jul 31, 2024 | clinicaltrials |
| NCT05864924 | A Phase 1 Study of BRG01 in Subjects With Relapsed/Metastatic Epstein-Barr Virus (EBV)-Positive Nasopharyngeal Carcinoma | completed | Phase 1 | 14 | BioSyngen Pte LtdINDUSTRY | 1 | May 8, 2024 | clinicaltrials |
| NCT04572100 | Pilot Study of Chemotherapy for HPV-Associated Oropharyngeal Cancer | completed | Phase 1 | 50 | University of ChicagoOTHER | 1 | Jul 7, 2023 | clinicaltrials |
| NCT01935921 | Ipilimumab, Cetuximab, and Intensity-Modulated Radiation Therapy in Treating Patients With Previously Untreated Stage III-IVB Head and Neck Cancer | completed | Phase 1 | 19 | National Cancer Institute (NCI)NIH | 1 | Jun 15, 2023 | clinicaltrials |
| NCT04413214 | Carrimycin in Patients With Locally Advanced, Recurrent, or Metastatic HNSCC (Non NPC): A Phase I Trial | completed | Phase 1 | 9 | Shanghai Jiao Tong University School of MedicineOTHER | 1 | Apr 5, 2023 | clinicaltrials |
| NCT03502148 | Safety and Efficacy Study of PRV111 in Subjects With Oral Squamous Cell Carcinoma(PRV111) | completed | Phase 1 / Phase 2 | 10 | Privo TechnologiesINDUSTRY | 1 | Oct 21, 2022 | clinicaltrials |
| NCT00470496 | Photodynamic Therapy Using HPPH in Treating Patients Undergoing Surgery for Primary or Recurrent Head and Neck Cancer | completed | Phase 1 | 15 | Roswell Park Cancer InstituteOTHER | 1 | Jul 25, 2022 | clinicaltrials |
| NCT02775812 | Cisplatin, Intensity-Modulated Radiation Therapy, and Pembrolizumab in Treating Patients With Stage III-IV Head and Neck Squamous Cell Carcinoma | completed | Phase 1 | 37 | National Cancer Institute (NCI)NIH | 1 | Jun 10, 2022 | clinicaltrials |
| NCT01816984 | PI3K Inhibitor BKM120 and Cetuximab in Treating Patients With Recurrent or Metastatic Head and Neck Cancer | completed | Phase 1 / Phase 2 | 12 | University of ChicagoOTHER | 1 | Oct 5, 2021 | clinicaltrials |
| NCT03144778 | Durvalumab With or Without Tremelimumab in Treating Participants With Stage II-IVA Oropharyngeal Squamous Cell Cancer | completed | Phase 1 | 39 | M.D. Anderson Cancer CenterOTHER | 1 | Mar 18, 2021 | clinicaltrials |
| NCT01254617 | Lenalidomide and Cetuximab in Treating Patients With Advanced Colorectal Cancer or Head and Neck Cancer(ADCC) | completed | Phase 1 | 24 | National Cancer Institute (NCI)NIH | 1 | Mar 13, 2020 | clinicaltrials |
| NCT01469429 | Phase 1b Food Based Modulation of Biomarkers in Human Tissues at High-Risk for Oral Cancer. | completed | Phase 1 / Phase 2 | 70 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Feb 20, 2020 | clinicaltrials |
| NCT01806675 | 18F-FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy | completed | Phase 1 / Phase 2 | 25 | Sanjiv Sam GambhirOTHER | 1 | Oct 3, 2019 | clinicaltrials |
| NCT01064921 | Ph I Vorinostat in the Treatment of Advanced Staged Oropharyngeal Squamous Cell Carcinoma | completed | Phase 1 | 27 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Jun 4, 2019 | clinicaltrials |
| NCT00055913 | Bevacizumab and Erlotinib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer | completed | Phase 1 / Phase 2 | 58 | National Cancer Institute (NCI)NIH | 1 | Oct 2, 2018 | clinicaltrials |
| NCT02035527 | Sorafenib Tosylate, Cisplatin, and Docetaxel in Treating Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck | completed | Phase 1 | 3 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | May 24, 2018 | clinicaltrials |
| NCT01921426 | A Phase 1 Dose Escalation Study of GC4419 in Combination With Chemoradiation for Squamous Cell Cancer of the Head & Neck | completed | Phase 1 | 30 | Galera Therapeutics, Inc.INDUSTRY | 1 | Sep 22, 2016 | clinicaltrials |
| NCT01108042 | TPF-Induction Chemotherapy of Oropharyngeal and Cavity of the Mouth Cancer | completed | Phase 1 / Phase 2 | 71 | Orlando Guntinas-Lichius, Prof. Dr. med.OTHER | 1 | May 18, 2016 | clinicaltrials |
| NCT00397384 | Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer | completed | Phase 1 | 43 | National Cancer Institute (NCI)NIH | 1 | Sep 30, 2015 | clinicaltrials |
| NCT01192204 | Clinical Evaluation of Bioadhesive Gels for Oral Cancer Chemoprevention | completed | Phase 1 / Phase 2 | 41 | Ohio State UniversityOTHER | 1 | Aug 14, 2015 | clinicaltrials |
| NCT01334177 | TLR8 Agonist VTX-2337 and Cetuximab in Treating Patients With Locally Advanced, Recurrent, or Metastatic Squamous Cell Cancer of Head and Neck | completed | Phase 1 | 13 | University of WashingtonOTHER | 1 | Mar 5, 2015 | clinicaltrials |
| NCT00101348 | Erlotinib and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney, Colorectal, Head and Neck, Pancreatic, or Non-Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 66 | National Cancer Institute (NCI)NIH | 1 | Jun 11, 2014 | clinicaltrials |
| NCT00049283 | Erlotinib, Docetaxel, and Radiation Therapy in Treating Patients With Locally Advanced Head and Neck Cancer | completed | Phase 1 | 30 | National Cancer Institute (NCI)NIH | 1 | Jun 6, 2014 | clinicaltrials |
| NCT00055770 | Erlotinib Plus Docetaxel in Treating Patients With Locally Advanced, Metastatic, or Recurrent Head and Neck Cancer | completed | Phase 1 / Phase 2 | 45 | National Cancer Institute (NCI)NIH | 1 | Nov 25, 2013 | clinicaltrials |
| NCT00031681 | 7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007) | completed | Phase 1 | 41 | National Cancer Institute (NCI)NIH | 1 | Sep 30, 2013 | clinicaltrials |
| NCT00049166 | Erlotinib and Radiation Therapy With or Without Cisplatin in Treating Patients With Mouth or Throat Cancer | completed | Phase 1 | 48 | National Cancer Institute (NCI)NIH | 1 | Sep 30, 2013 | clinicaltrials |
| NCT00089362 | Alvespimycin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors | completed | Phase 1 | 30 | National Cancer Institute (NCI)NIH | 1 | Apr 10, 2013 | clinicaltrials |
| NCT00004074 | Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu | completed | Phase 1 | 15 | National Cancer Institute (NCI)NIH | 1 | Feb 28, 2013 | clinicaltrials |
| NCT00023959 | Bevacizumab, Fluorouracil, and Hydroxyurea Plus Radiation Therapy in Treating Patients With Advanced Head and Neck Cancer | completed | Phase 1 | 39 | National Cancer Institute (NCI)NIH | 1 | Feb 7, 2013 | clinicaltrials |
| NCT00030498 | Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction | completed | Phase 1 | 75 | National Cancer Institute (NCI)NIH | 1 | Jan 16, 2013 | clinicaltrials |
| NCT00063895 | Erlotinib in Treating Patients With Advanced Non-Small Cell Lung Cancer, Ovarian Cancer, or Squamous Cell Carcinoma of the Head and Neck | completed | Phase 1 / Phase 2 | 80 | National Cancer Institute (NCI)NIH | 1 | Jan 9, 2013 | clinicaltrials |
| NCT01637194 | Cetuximab and Everolimus in Treating Patients With Metastatic or Recurrent Colon Cancer or Head and Neck Cancer | completed | Phase 1 | 12 | Fox Chase Cancer CenterOTHER | 1 | Jul 11, 2012 | clinicaltrials |
Data updated 23 days agoSource updated Apr 2, 2026source: clinicaltrials